When someone asks you to justify a pharmacist’s role in chronic disease management, you now have a peer-reviewed answer. Not from a small pilot. Not from a controlled trial with ideal conditions. From four years of real-world data in a real specialty clinic with real patients, the kind of patients most programs avoid because they’re too hard to move.
The Study and Why It Matters
The study, published in PLOS ONE in March 2026, followed 239 patients enrolled in the Diabetes Care Coach program, all with uncontrolled blood glucose levels and a mean A1c of 10.3%, and matched them against 815 peers receiving usual specialty diabetes care at the same clinic. Same patient population. Same clinical setting. The only difference was the coaching.
A retrospective matched-cohort design compared adults with persistent A1c ≥ 9% who enrolled in the Diabetes Care Coach program with propensity-matched peers also receiving specialty diabetes care but not enrolled in the program. Data came from the UMass Memorial Health electronic health record and the UMass Memorial Medicare Accountable Care Organization claims database from January 2020 to December 2023.
This is the most methodologically rigorous real-world evaluation of a pharmacist-led diabetes coaching model to date. Four years. 239 coached patients. 815 matched controls. All at a single specialty diabetes clinic in Worcester, Massachusetts.
The Clinical Numbers That Demand Attention
The average A1c reduction among coach-supported patients was 1.5 percentage points, a result that outperforms the typical outcomes seen in randomized controlled trials of coaching interventions. For a population this hard to move, that result is meaningful.
For context: tirzepatide, the most potent approved pharmacotherapy for type 2 diabetes, produces A1c reductions of approximately 2.0–2.3% in clinical trials, in patients who aren’t necessarily starting from a mean A1c of 10.3%. This program moved severely uncontrolled patients by 1.5 points through coaching, not drugs.
But the number that gets health system leaders to act is never the A1c. It’s the utilization data.
For every 100 patients enrolled in the program, there were approximately 15 fewer emergency department visits, 22 fewer hospital admissions, and 3.7 fewer total hospital days compared to matched peers over the study period.
22 fewer hospital admissions per 100 patients. In a patient population with mean A1c of 10.3%, that number represents serious decompensation events, DKA presentations, hypoglycemic emergencies, infection hospitalizations, that never happened because a pharmacist stayed in the gap between appointments.
The Financial Model That Makes It Sustainable
The PLOS ONE paper went beyond clinical outcomes to address the question every pharmacy director and health system CFO will ask: does it pay for itself?
Within the ACO subgroup, intervention participants had a greater mean reduction in annual total medical expenditure of $2,649 per patient, nearly identical to the program’s operating cost of approximately $2,800 per patient. Internal financial data showed that improved medication adherence yielded additional specialty pharmacy and 340B revenue sufficient to offset program costs. This break-even profile suggests that pharmacist-led coaching may be capable of self-financing under current payment models.
With approximately one-third of participants carrying Medicaid insurance, the sustainability of such programs increases through leveraging the 340B program to enhance care for economically vulnerable patients. As value-based contracts mature, any future shared savings dollars or revenue retained from avoided utilization could be reinvested in services that address the social drivers of uncontrolled diabetes.
A program that produces measurable A1c reduction, 22 fewer hospitalizations per 100 patients, and essentially breaks even on direct costs before accounting for shared savings is not a demonstration project. It is a deployable clinical model.
What the Coaching Actually Looks Like
The clinical results didn’t emerge from medication optimization alone. The program pairs patients with pharmacist coaches who expand support beyond medications to include lifestyle needs, social determinants, and mental health. “Every patient is unique, and what’s great about the program is that we give coaches the bandwidth to really tailor care and listen to the patient story,” said Bill McElnea, VP of Population Health at Shields Health Solutions. “Nutrition, lifestyle, and motivation all play a big role in helping patients stay on track.”
Patients receive frequent in-person or telehealth visits with a diabetes-trained clinical pharmacist. Sessions run up to an hour at the start and scale back to 30 minutes as the relationship matures and the patient gains confidence managing their between-appointment care.
The coach-to-patient model works because it solves a structural problem in diabetes care, not a pharmacological one. Most patients with uncontrolled diabetes don’t have a medication that isn’t working. They have a barrier that isn’t being addressed: cost, confusion, fear of insulin, competing stressors, food insecurity, social isolation, or simply no one who follows up between quarterly specialist visits.
The program produced medication adherence rates of approximately 95% among enrolled patients, compared to near-zero prior to enrollment. The improvement in adherence alone accounts for a meaningful portion of the A1c gains, since the gap between prescribed and taken was the primary clinical problem for many of these patients.
One patient, Michael O’Rourke, had managed type 2 diabetes for over 40 years without proactive self-management. After one year in the coaching program, his A1c dropped from 8.5% to 6.4%. His pharmacist coach described using a continuous glucose monitor as the turning point, not a new medication, a new relationship with his own data.
What This Means for Your Practice Right Now
The Shields-UMass model runs within a specialty diabetes clinic with health system infrastructure. Most pharmacists don’t have that infrastructure. But the underlying clinical logic is fully replicable at any practice level, and it starts with one question: who in my patient panel is most stuck?
Look at your current diabetes panel. Find the five patients with the highest A1c, the ones who haven’t moved despite medication adjustments, refill reminders, and standard counseling. Those five patients are your proof of concept.
Assign each one a structured monthly pharmacist touchpoint. Not a refill reminder. A 10-minute clinical conversation with one defined agenda: identify one specific barrier, cost, side effects, dietary confusion, fear of hypoglycemia, social circumstances, motivation, and address it directly.
The A1c reductions in the PLOS ONE study didn’t come from better drugs. They came from consistent relationships that showed up between appointments, not just during them. The program was built on a simple premise: high-risk patients with diabetes need more than a specialist they see three times a year.
That premise doesn’t require a health system partnership to test. It requires a patient list, a pharmacist, and 10 minutes a month.
The Case This Study Makes for the Profession
The PLOS ONE data arrives at a specific moment in pharmacy advocacy. The profession is actively fighting for provider status recognition, Medicare billing authority, and inclusion in value-based payment models. The argument for all three is exactly what this study demonstrates: pharmacists produce measurable clinical outcomes, reduce utilization, and do it in a financially sustainable model.
The program’s break-even financial profile, combined with its clinical outcomes, suggests that pharmacist-led coaching may be capable of self-financing under current payment models, and that value-based contracts would make it definitively revenue-positive.
When your state pharmacy association goes to the statehouse to argue for provider status, this is the kind of evidence that belongs in the testimony. When a health system wants to know whether a pharmacy-integrated care model delivers ROI, this is the peer-reviewed answer. When a patient asks why they should spend time with a pharmacist instead of just picking up their prescription, this is the story you tell.
Four years of data. 239 patients with a mean A1c of 10.3%. 22 fewer hospital admissions per 100 patients. The pharmacist-led model won, decisively. In real patients. In a real clinic. In PLOS ONE.
Sources: PLOS ONE (Amante D et al. Effectiveness of a Pharmacist Diabetes Coaching Program: A Propensity-Matched Retrospective Analysis, March 2026. DOI: 10.1371/journal.pone.0345534), Shields Health Solutions Blog (How a New Pharmacist-Led Diabetes Support Program Is Filling the Gap Between Appointments, April 2026), UMass Memorial Health (Diabetes Coach Care Program Expands Support and Improves Outcomes for Patients), UMass Memorial Health The Pursuit (Diabetes Care Coach Program Reduces Patients’ Costs, Improves Outcomes), Managed Healthcare Executive (Specialty Pharmacy Coaching Model Tied to Lower Costs, Improved Diabetes Outcomes — Asembia AXS26 Summit Coverage, April 2026), American Diabetes Association (1048-P: A Financially Sustainable Pharmacist Plus Care Model Shows Superior Diabetes Outcomes, Diabetes Supplement 2024)